Incretins: Beyond type 2 diabetes

被引：9
作者：
Dandona, Paresh [1 ]
Ghanim, Husam [1 ]
Chaudhuri, Ajay [1 ]
机构：
[1] SUNY Buffalo, Diabet Endocrinol Ctr Western NY, 1000 Youngs Rd, Buffalo, NY 14221 USA
来源：
DIABETES OBESITY & METABOLISM | 2018年 / 20卷
关键词：
cardiovascular disease; diabetic nephropathy; incretins; type; 1; diabetes; weight control; DIPEPTIDYL PEPTIDASE-IV; ADDITIONAL TREATMENT; RECEPTOR AGONISTS; DOUBLE-BLIND; WEIGHT-LOSS; CARDIOVASCULAR OUTCOMES; INSULIN-TREATMENT; GLYCEMIC CONTROL; CONTROLLED-TRIAL; BLOOD-PRESSURE;
D O I：
10.1111/dom.13153
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
While the use of incretins, including GLP-1 receptor agonists and PDD-IV inhibitors, is well established in the treatment of type 2 diabetes, many other aspects of these agents are yet to be discovered and utilized for their potential clinical benefit. These include the potential role of GLP-1 receptor agonists in the induction of weight loss, blood pressure reduction, anti-inflammatory and nephro- and cardio-protective actions. Their potential benefit in type 1 diabetes is also being investigated. This review will attempt to comprehensively describe novel discoveries in the field of incretin pathophysiology and pharmacology beyond their classical role in the treatment of type 2 diabetes.
引用
收藏
页码：59 / 67
页数：9
相关论文
共 94 条
  • [71] REDUCED INCRETIN EFFECT IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES
    NAUCK, M
    STOCKMANN, F
    EBERT, R
    CREUTZFELDT, W
    [J]. DIABETOLOGIA, 1986, 29 (01) : 46 - 52
  • [72] Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
    Patil, Harshal R.
    Al Badarin, Firas J.
    Al Shami, Hamza A.
    Bhatti, Salman K.
    Lavie, Carl J.
    Bell, David S. H.
    O'Keefe, James H.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (06) : 826 - 833
  • [73] Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
    Perkins, Bruce A.
    Cherney, David Z. I.
    Partridge, Helen
    Soleymanlou, Nima
    Tschirhart, Holly
    Zinman, Bernard
    Fagan, Nora M.
    Kaspers, Stefan
    Woerle, Hans-Juergen
    Broedl, Uli C.
    Johansen, Odd-Erik
    [J]. DIABETES CARE, 2014, 37 (05) : 1480 - 1483
  • [74] Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition
    Peters, Anne L.
    Buschur, Elizabeth O.
    Buse, John B.
    Cohan, Pejman
    Diner, Jamie C.
    Hirsch, Irl B.
    [J]. DIABETES CARE, 2015, 38 (09) : 1687 - 1693
  • [75] A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
    Pi-Sunyer, Xavier
    Astrup, Arne
    Fujioka, Ken
    Greenway, Frank
    Halpern, Alfredo
    Krempf, Michel
    Lau, David C. W.
    le Roux, Carel W.
    Violante Ortiz, Rafael
    Jensen, Christine Bjorn
    Wilding, John P. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (01) : 11 - 22
  • [76] Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
    Pieber, T. R.
    Famulla, S.
    Eilbracht, J.
    Cescutti, J.
    Soleymanlou, N.
    Johansen, O. E.
    Woerle, H. J.
    Broedl, U. C.
    Kaspers, S.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (10) : 928 - 935
  • [77] Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients
    Pugazhenthi, U.
    Velmurugan, K.
    Tran, A.
    Mahaffey, G.
    Pugazhenthi, S.
    [J]. DIABETOLOGIA, 2010, 53 (11) : 2357 - 2368
  • [78] Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation
    Reinhold, Dirk
    Biton, Aliza
    Pieper, Stefanie
    Lendeckel, Uwe
    Faust, Juergen
    Neubert, Klaus
    Bank, Ute
    Taeger, Michael
    Ansorge, Siegfried
    Brocke, Stefan
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (13-14) : 1935 - 1942
  • [79] Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial
    Retnakaran, Ravi
    Kramer, Caroline K.
    Choi, Haysook
    Swaminathan, Balakumar
    Zinman, Bernard
    [J]. DIABETES CARE, 2014, 37 (12) : 3270 - 3278
  • [80] PHARMACOKINETIC, INSULINOTROPIC, AND GLUCAGONOSTATIC PROPERTIES OF GLP-1 [7-36-AMIDE] AFTER SUBCUTANEOUS INJECTION IN HEALTHY-VOLUNTEERS - DOSE-RESPONSE-RELATIONSHIPS
    RITZEL, R
    ORSKOV, C
    HOLST, JJ
    NAUCK, MA
    [J]. DIABETOLOGIA, 1995, 38 (06) : 720 - 725
12345678910